Sign up
Pharma Capital

Zelda Therapeutics enters medical cannabis research partnership

The halt will remain in place until Tuesday 12th December 2017.
1512685661_1-Imperial-Innovations-(2).jpg
The company's shares are in pre-open

Zelda Therapeutics Ltd (ASX:ZLD) continues to advance its medical cannabis strategy, and the company entered a trading halt this morning pending details of a partnership with a US-based research institution.

READ: Zelda approved for Australia’s first medicinal cannabis trial targeting insomnia

The halt will remain in place until the opening of trade on Tuesday 12th December 2017, or earlier if an announcement is made to the market.



Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.